bullish

Eubiologics

EuBiologics (206650 KS): Base Business Recovery; COVID Vaccine Undergoing Phase 3 Trial

360 Views18 Mar 2022 17:09
SUMMARY
  • Eubiologics (206650 KS) signed contract with UNICEF to deliver 67.1 million doses of its oral cholera vaccine, Euvichol-Plus, through 2023. Euvichol-Plus is the cash cow for the company.
  • The company’s COVID-19 vaccine EuCorVac-19 is in phase 3 trial and is one of the early movers among Korean vaccine manufacturers in terms of clinical timeline.
  • EuBiologics has successfully diversified portfolio and its pipeline of non-cholera vaccine and non-vaccine product candidates are also progressing, thereby lending long-term visibility beyond COVID.
Get started on the Smartkarma Research Network with a complimentary Preview Pass to:
  • Unlock all research summaries
  • Follow top, independent analysts
  • Receive personalised alerts and emails
  • Access Briefings, Analytics, and Events

Upgrade anytime to our paid plans for full-length research, real-time analyst discussions, and more.

Join a thriving community of 45,000+ investors, including the top global asset managers managing over $13trn in assets.

or
Already have an account? Sign In Now
Discussions
(Paid Plans Only)
chart-bar
x